Statement of the Uterus Committee of the Gynaecological Oncology Working Group (AGO) on the PORTEC-3 study

Günther Emons; Clemens Tempfer; Marco Johannes Battista; Alexander Mustea; Dirk Vordermark

doi:10.1055/a-0658-1918

Geburtshilfe und Frauenheilkunde, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2018; 78(10): 923-926
DOI: 10.1055/a-0658-1918

GebFra Science

Statement/Stellungnahme

Georg Thieme Verlag KG Stuttgart · New York

Statement of the Uterus Committee of the Gynaecological Oncology Working Group (AGO) on the PORTEC-3 study

Artikel in mehreren Sprachen: English | deutsch

Authors

Günther Emons

¹Universitätsmedizin Göttingen, Göttingen, Germany
Clemens Tempfer

²Ruhr Universität Bochum, Bochum, Germany
Marco Johannes Battista

³Universitätsklinikum Mainz, Mainz, Germany
Alexander Mustea

⁴Universitätsmedizin Greifswald, Greifswald, Germany
Dirk Vordermark

⁵Universitätsklinik Halle (Saale), Halle (Saale), Germany

Abstract

The data on the adjuvant therapy of endometrial cancer (EC) are inconsistent. Recent studies of this topic such as PORTEC-3, GOG-258 and GOG-249 investigated the value of adjuvant radiotherapy, adjuvant chemotherapy and combined adjuvant chemoradiotherapy followed by chemotherapy in patients with endometrial cancer and an increased risk of recurrence. With this statement, the Uterus Committee of the Gynaecological Oncology Working Group (AGO) wishes therefore to interpret the new data and discuss them against the background of the new S3 guideline “Diagnosis, treatment and follow-up of patients with endometrial cancer”.

Key words

endometrial cancer - adjuvant therapy - chemotherapy - radiotherapy - recurrence

Volltext

Referenzen

References/Literatur
1 Matei D, Filiaci V, Randall M. et al. A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma. J Clin Oncol 2017; 35 (Suppl.) Abstract 5505
2 The ASCO Post. ASTRO 2017: GOG-249 confirms adjuvant pelvic radiation as standard of care for high-risk, early-stage endometrial cancer. Online: http://www.ascopost.com/News/58092 last access: 23.01.2018
3 De Boer SM, Powell ME, Mileshkin L. et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicenter, randomized, phase 3 trial. Lancet Oncol 2018; 19: 295-309
4 S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientinnen mit Endometriumkarzinom. Version 1.0 – April 2018 AWMF-Registernummer: 032/034-OL. Online: https://www.leitlinienprogramm-onkologie.de/leitlinien/endometriumkarzinom/ last access: 30.05.2018
5 Nout RA, van de Poll-Franse LV, Lybeert ML. et al. Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. J Clin Oncol 2011; 29: 1692-1700
6 Nout RA, Smit VT, Putter H. et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010; 375: 816-823